Dr. Bastyr is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
720 Eskenazi Ave
# Univ
Indianapolis, IN 46202Phone+1 317-880-5045Fax+1 317-880-0414
Summary
- Dr. Edward Bastyr is an endocrinologist in Indianapolis, IN and is affiliated with Eskenazi Health. He received his medical degree from Universidad de Navarra Faculty of Medicine and has been in practice 34 years. He also speaks multiple languages, including Spanish. He specializes in diabetes and lipid metabolism and is experienced clinical researcher in diabetes mellitus and obesity and obesity-related disorders.
Education & Training
- University of MichiganFellowship, Endocrinology, Diabetes, and Metabolism, 1985 - 1988
- UPMC Medical Education/MercyResidency, Internal Medicine, 1983 - 1985
- UPMC Medical Education/MercyInternship, Internal Medicine, 1982 - 1983
- Universidad de Navarra Faculty of MedicineClass of 1982
- Wagner CollegeMS, Microbiology, 1977 - 1978
- University of ChicagoMS, Biochemistry, 1976 - 1977
- Columbia College, Columbia UniversityAB, Biochemistry, 1972 - 1976
Certifications & Licensure
- IN State Medical License 1995 - 2025
- PA State Medical License 1983 - 2024
- TX State Medical License 1989 - 1996
- MI State Medical License 1985 - 1992
- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Endocrinology, Diabetes and Metabolism
Awards, Honors, & Recognition
- President's Recognition Award For Outstanding Scientific Achievement (1% Award) Lilly Research Laboratories, 2002, 2009, 2014
- Lincoln Fund Fellow Rockefeller University, 1975
- Honorarium University of Pittsburgh, 1973
Publications & Presentations
PubMed
- 213 citationsThe Sustained Effects of a Dual GIP/GLP-1 Receptor Agonist, NNC0090-2746, in Patients with Type 2 Diabetes.Juan Pablo Frias, Edward J. Bastyr, Louis Vignati, Matthias H. Tschöp, Christophe Schmitt
Cell Metabolism. 2017-08-01 - 6 citationsLatex Allergen Allergic ReactionsEdward J. Bastyr
Diabetes Care. 1996-05-01 - 14 citationsThe PNPLA3 I148M variant is associated with transaminase elevations in type 2 diabetes patients treated with basal insulin peglisproSreekumar G. Pillai, Suman Duvvuru, Pallav Bhatnagar, Wendra M. Foster, M Farmen
The Pharmacogenomics Journal. 2018-05-22
Journal Articles
- The PNPLA3 I148M Variant is Associated with Transaminase Elevations in Type 2 Diabetes (T2D) Patients Treated with Basal Insulin Peglispro (BIL)Pillai S, Duvvuru S, Bhatnagar P, Foster W, Farmen M, Shankar S, Harris C, Bastyr EJ III, Hoogwerf B, and A Haupt, The Pharmacogenomics Journal, 1/1/2016
- Different effects of basal insulin peglispro and insulin glargine on liver enzymes and liver fat content in patients with type 1 and type 2 diabetesCusi K, Sanyal AJ, Zhang S, Hoogwerf BJ, Chang AM, Jacober SJ, Bue-Valleskey JM,Higdon AN, Bastyr EJ III, Haupt A and Hartman ML, Diabetes, Obesity and Metabolism, 1/1/2016
- Reduced Nocturnal Hypoglycemia with Basal Insulin Peglispro Compared to Insulin Glargine (GL): Pooled Analyses of 5 Randomized Controlled TrialsRosenstock J, Marre M, Qu Y, Zhang S, Bastyr EJ III, Prince MJ, Chang AM, Diabetes, Obesity and Metabolism, 1/1/2016
- Join now to see all
Abstracts/Posters
- Greater HbA1c Reduction with Basal Insulin Peglispro (BIL) v Insulin Glargine (GL) in an Open-label, Randomized Study in T1D Patients (pts): IMAGINE 1Garg SK, Jinnouchi H, Dreyer M, Mou J, Hartman ML, Rosilio M, Bastyr EJ III for the IMAGINE 1 Study Group, American Diabetes Association National Meeting; Diabetes, Boston, MA, 1/1/2015
- Superior HbA1c Reduction with Basal Insulin Peglispro (BIL) vs Insulin Glargine (GL) and Preprandial Insulin Lispro in a Double-blind Study in Patients (pts) with Type...Blevins T, Pieber TR, Vega GC, Zhang S, Bastyr EJ III, Chang AM, American Diabetes Association National Meeting; Diabetes, Boston, MA, 1/1/2015
- Superior Reduction of HbA1c in a Double-blind, Randomized Study of Basal Insulin Peglispro (BIL) v Insulin Glargine (GL) in Patients (pts) with T1D: IMAGINE 3Bergenstal RM, Lunt H, Franek E, Travert F, Mou J, Hartman ML, Rosilio M, Bastyr EJ III for the IMAGINE 3 Study Group, American Diabetes Association National Meeting; Diabetes, Boston, MA, 1/1/2015
- Join now to see all
Lectures
- Electronic Data Capture in Insulin Management for Patients (pts) with Type 1 (T1DM) and Type 2 (T2DM) Diabetes Mellitus in Global Clinical TrialsIndianapolis, IN - 6/14/2014
- LY2605541, A Novel Long-Acting Basal Insulin AnalogColegio de Medicos de España, Madrid, Spain - 1/1/2012
- Postprandial Blood Glucose is a Better Predictor of Overall Metabolic Control in Diabetes MellitusNorfolk, VA - 1/1/2000
- Join now to see all
Professional Memberships
- Member
- European Association for the Study of DiabetesMember
Other Languages
- Spanish
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: